Patents by Inventor Michael McDonell

Michael McDonell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6749857
    Abstract: The present invention discloses and claims vaccines containing, as an active ingredient, a secreted recombinantly produced dimeric form of truncated flaviviral envelope protein. The vaccines are capable of eliciting the production of neutralizing antibodies against flaviviruses. The dimeric forms of truncated flaviviral envelope protein are formed 1) by directly linking two tandem copies of 80% E in a head to tail fashion via a flexible tether; 2) via the formation of a leucine zipper domain through the homodimeric association of two leucine zipper helices each fused to the carboxy terminus of an 80% E molecule; or 3) via the formation of a non-covalently associated four-helix bundle domain formed upon association of two helix-turn-helix moieties each attached to the carboxy terminus of an 80% E molecule.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: June 15, 2004
    Assignee: Hawaii Biotechnology Group, Inc.
    Inventors: Iain D. Peters, Beth-Ann G. Coller, Michael McDonell, John M. Ivy, Kent Harada
  • Publication number: 20030175304
    Abstract: The present invention discloses and claims vaccines containing, as an active ingredient, a secreted recombinantly produced dimeric form of truncated flaviviral envelope protein. The vaccines are capable of eliciting the production of neutralizing antibodies against flaviviruses. The dimeric forms of truncated flaviviral envelope protein are formed 1) by directly linking two tandem copies of 80% E in a head to tail fashion via a flexible tether; 2) via the formation of a leucine zipper domain through the homodimeric association of two leucine zipper helices each fused to the carboxy terminus of an 80% E molecule; or 3) via the formation of a non-covalently associated four-helix bundle domain formed upon association of two helix-turn-helix moieties each attached to the carboxy terminus of an 80% E molecule.
    Type: Application
    Filed: September 20, 2002
    Publication date: September 18, 2003
    Inventors: Iain D. Peters, Beth-Ann G. Coller, Michael McDonell, John M. Ivy, Kent Harada
  • Patent number: 6432411
    Abstract: A vaccine contains at least one Drosophila cell-secreted, recombinantly-produced form of a truncated Flavivirus envelope glycoprotein, as an active ingredient, and an adjuvant, as a critical component of the vaccine. The adjuvant is an immunomodulating agent having an iscom-like structure and comprising within the iscom-like structure at least one lipid and at least one saponin, and a pharmaceutically acceptable vehicle. Such a vaccine protects a subject against infection by a Flavivirus.
    Type: Grant
    Filed: July 13, 1999
    Date of Patent: August 13, 2002
    Assignee: Hawaii Biotechnology Group
    Inventors: John Ivy, Gary Bignami, Michael McDonell, David E. Clements, Beth-Ann G. Coller
  • Patent number: 6416763
    Abstract: The recombinant expression and secretion from eucaryotic host cells, particularly Drosophila cells, of Flavivirus nonstructural (NS) protein, particularly NS1, is useful in combination with Flavivirus truncated envelope (E) protein to protect a host subject from infection and disease from Flavivirus species. Further, NS1 is useful as a diagnostic of flaviviral infection. Compositions of truncated flaviviral envelope protein and flaviviral nonstructural protein induce high titer virus neutralizing antibodies believed to be important in protection against flaviviral infection and which are useful in diagnosis of infection by the virus.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: July 9, 2002
    Assignee: Hawaii Biotechnology Group, Inc.
    Inventors: Michael McDonell, Iain Peters, Beth-Ann Coller
  • Publication number: 20020076221
    Abstract: An apparatus for discharging effluent from a photographic process, such as developing liquid to a drain. The effluent can be, for example, de-silvered, spent fixer liquid, and spent developer liquid, which if mixed together, particularly in the presence of oxygen, form a solid iron oxide precipitate which becomes a sludge and eventually clogs pipes and drains. The apparatus includes two separate reservoirs for holding the liquids and two separate pumps for pumping the liquids to a drain, while reducing the risk of clogging in the pipes and drain from precipitate formation.
    Type: Application
    Filed: December 14, 2000
    Publication date: June 20, 2002
    Inventor: Michael McDonell